Company news
Abivax Sa (EURONEXT:ABVX) news
Abivax Sa news releases on 6ix. Latest, Sep 30, 2026: Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Press releases & updates
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
September 30, 2026
Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026
September 29, 2026
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26
September 24, 2026
Abivax Presents Business Updates and First Half 2026 Financial Results
September 21, 2026
Abivax Presents Business Updates and First Half 2026 Financial Results
September 21, 2026
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
July 30, 2026
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
July 23, 2026
Abivax Announces Closing of $920 Million Public Offering
July 6, 2026
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
July 2, 2026
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
July 1, 2026
Abivax Announces Launch of Public Offering of American Depositary Shares
June 30, 2026
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
June 29, 2026
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
June 29, 2026
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
June 1, 2026
Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
May 22, 2026
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
May 22, 2026
Abivax Announces Results of its May 11, 2026 Annual General Meeting
May 11, 2026
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (EUR38.5M) Offering of American Depositary Shares
May 7, 2026
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
May 5, 2026
Abivax to Present Data on Obefazimod at Digestive Disease Week®
April 22, 2026
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
April 20, 2026
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
April 1, 2026
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
February 21, 2026
Abivax Provides 2026 Corporate Outlook
January 7, 2026
Abivax to be Added to Nasdaq Biotechnology Index
December 18, 2025
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
December 17, 2025
Abivax Presents Third Quarter 2025 Financial Results
December 15, 2025
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
November 3, 2025
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
October 6, 2025
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
October 5, 2025
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
September 29, 2025
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
September 23, 2025
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
September 12, 2025
Abivax Presents First Half 2025 Financial Results
September 8, 2025
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
August 11, 2025
Abivax Announces Closing of $747.5 Million Public Offering
July 28, 2025
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
July 25, 2025
Abivax announces trading resumption of its ordinary shares on Euronext Paris
July 24, 2025
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
July 24, 2025
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 24, 2025
Abivax Announces Launch of Public Offering
July 23, 2025
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
July 22, 2025
Abivax Announces Results of its June 6, 2025 Annual General Meeting
June 11, 2025
Abivax Presents First Quarter 2025 Financial Results
June 2, 2025
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
April 29, 2025
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
April 22, 2025
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
April 22, 2025